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The search for potential biomarkers of psychiatric disorders is a central topic in biological
psychiatry. This review concerns published studies on potential biomarkers of treatment-
resistant depression (TRD). The search for biomarkers of TRD in the bloodstream has
focused on cytokines and steroids as well as brain-derived neurotropic factor. Additional
approaches to identifying biomarkers of TRD have dealt with cerebrospinal fluid analysis,
magnetic resonance imaging, and positron emission tomography. Some studies have also
investigated potential genetic and epigenetic factors in TRD. Most studies have, however,
used a post hoc experimental design that failed to determine the association between bio-
markers and the initial risk ofTRD. Particular attention in future studies should be on shifting
the experimental paradigm toward procedures that can determine the risk for developing
treatment resistance in untreated depressed individuals.
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“The development and use of a biomarker to identify ‘at risk’
individuals and to diagnose and/or quantify mental illness is
the “holy grail” of psychiatry.” (Macaluso and Preskorn, 2012)
Treatment-resistant depression (TRD) continues to challenge
medical and psychological services worldwide (Rush et al., 2009;
Wittchen et al., 2011; Schosser et al., 2012; Xiang et al., 2012). One
way to meet these challenges would be to determine the molecular
causes responsible for treatment resistance and then to develop
effective treatments to help patients achieve complete remission
of symptoms. That goal is, however, currently out of reach. Surely,
some advances have been made toward identifying clinical risk
factors for TRD along with biomarkers of affective disorders and
antidepressant response (Uher et al., 2012; Perlis, 2013; Schneider
and Prvulovic, 2013), but we still know next-to-nothing about risk
factors for TRD (Figure 1). Our lack of information on the ini-
tial risk of TRD is, I believe, mainly due to the nature of research
designs used traditionally in studies on potential biomarkers of
TRD.
RESEARCH DESIGN IN PUBLISHED STUDIES OF
BIOMARKERS IN TRD
“Once upon a time, two cars collided on a bright sunny day. When
a policeman arrived at the scene, he observed that a headlight
was broken on one of the cars. Based on that evidence, the officer
concluded that the accident was caused by a defective headlight.”
This fictitious, little tale illustrates the post hoc, ergo propter hoc
fallacy (Ingle, 1972; Bowell and Kemp, 2005); it occurs when a
situation observed after an event is thought to have caused the
event. Errors of reasoning are surprisingly common in everyday
life (Gilovich, 1993), but scientists are expected to do whatever
they can to avoid them. As a result, the interpretation of findings
in research projects is thought to reflect particularly critical reason-
ing (Martin, 1997). With regard to TRD, most studies of potential
biomarkers are typically carried out in individuals that are already
known to have the condition. As a result, the findings from such
studies can rightfully be viewed only as the consequences of hav-
ing TRD, rather than being predictive, causal, risk factors for the
disorder.
DEFINITIONS OF TRD
Treatment-resistant depression is a particularly serious condition
in urgent need of appropriate care. While the jury is still out con-
cerning the definition of TRD (Ruhe et al., 2012), most studies use
the criteria of an episode of major depressive disorder that has not
improved after at least two adequate trials of different classes of
antidepressants in a person who has complied by taking the pre-
scribed medication (Thase and Rush, 1995; Fava, 2003; Berlim and
Turecki, 2007; Berlim et al., 2008). In the author’s experience, by
the time that someone with major depressive disorder fulfills those
criteria, she has experienced a prolonged and extremely stressful
period, characterized by intense feelings of despair, punctuated
by suicidal thinking and a longing for relief from the unrelenting
horrors of the disabling condition. Thus, post hoc biomarkers of
TRD are of limited benefit for reducing the burden of disease.
LITERATURE SEARCH
This review is based mainly on reports retrieved via PubMed for
reports published after 1980 and identified by the following set of
keywords: human depression biomarker treatment resistant. The
reference lists of the retrieved articles were searched for further
reports of interest. For inclusion in this review, articles must have
presented a working definition of TRD and examined a potential
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FIGURE 1 | Annual number of publications on biomarkers of human
depressive disorders (diamonds) and on biomarkers of human
treatment-resistant depression (circles).
biomarker in subjects known at some time to have the condition.
No exclusion criteria were placed on the type of biomarker with
regard to peripheral and central bio-molecular processes. The aim
of this paper is to review the literature on biomarkers of TRD with
the intention of demonstrating the necessity of shifting the exper-
imental paradigm away from post hoc designs toward studies that
focus on early identification of depressed individuals at risk for
treatment failure.
PERIPHERAL BIOMARKERS
CYTOKINES AND STEROIDS
The immune response system (IRS) and hypothalamus-pituitary-
adrenal (HPA) axis have attracted attention in studies on poten-
tial biomarkers of TRD in biological psychiatry (Pariante and
Miller, 2001; Rothschild, 2003; Miller et al., 2009; Dowlati et al.,
2010). Bauer and coworkers published two closely related reports
on immune mechanisms in patients with well-established TRD
(Bauer et al., 2002, 2003). They estimated IRS activity by mea-
suring cortisol levels in saliva samples, mitogenic proliferation
capacity of lymphocytes, cytokine production in stimulated and
non-stimulated and blood cells, and dexamethasone suppression
of the HPA axis. The suppressant action of dexamethasone on
tumor necrosis factorα (TNFα) tended to be less in TRD inpatients
than in healthy subjects, whereas other biomarkers failed to dif-
fer between the two groups. Bauer and coworkers noted, however,
that their findings failed to settle questions concerning predictive
biomarkers of TRD. Later, O’Brien et al. (2007) measured plasma
cytokine levels in depressed subjects. Their study included sub-
jects who had failed to benefit from a single trial with a selective
serotonin reuptake inhibitor (SSRI), which fails to fulfill common
criteria for TRD. Plasma levels of TNFα and interleukin-6 were,
nevertheless, higher in depressed subjects that were resistant to
SSRI than in previously depressed, euthymic subjects that had
benefited from an SSRI, but the post hoc experimental design can-
not indicate whether plasma cytokine levels are reliable predictive
biomarkers of TRD. In fact, a recent study by Raison et al. (2013)
refutes the notion that high plasma levels of TNFα are involved
in non-response to antidepressant drugs. They used infliximab, a
monoclonal antibody which blocks TNFα, to test that notion and
found no reliable relationship between experimentally induced,
altered TNFα levels and antidepressant drug effects in individuals
with TRD.
Markopoulou et al. (2009) investigated possible links between
TRD and hyperactivity in the HPA axis. They recruited healthy
subjects and inpatients with well-established TRD and measured
blood levels of cortisol and dehydroepiandrosterone (DHEA). The
ratio of cortisol and DHEA was used as a measure of overall
glucocorticoid activity. They found that plasma levels of corti-
sol and cortisol/DHEA ratios were higher in TRD inpatients than
in healthy subjects, but there was no correlation between the bio-
markers and the clinical condition of patients. Markopoulou and
coworkers cautiously concluded that the extent to which abnor-
malities in adrenal gland function are instrumental in the genesis
of TRD remains unclear.
BRAIN-DERIVED NEUROTROPHIC FACTORS
Brain-derived neurotrophic factors (BDNF) is the most prevalent
growth factor in the central nervous system where it affects neu-
ronal development and neuroplasticity (Sen et al., 2008; Autry
and Monteggia, 2012). Fernandes et al. (2009) measured BDNF
levels in serum to see whether the molecule in the peripheral cir-
culation provides a reliable predictive biomarker for the effect
of electroconvulsive therapy (ECT) in subjects with TRD. They
found, however, that serum levels of BDNF failed to predict the
response rate to ECT.
Anttila et al. (2007) examined the possibility that a combi-
nation of genetic polymorphisms for BDNF and serotonin type
1A (5-HT1A) receptors might be involved in TRD. They used
blood samples to compare the genotypes of subjects with well-
established TRD and healthy blood donors. They found that a
particular combination of 5-HT1A and BDNF genotypes was
associated with TRD. Since genetic factors are viewed as stable bio-
molecular items, such findings may eventually provide biomarkers
for predicting the risk of someone having TRD.
EPIGENETICS
The term “epigenetics” means “outside conventional genetics.”
Epigenetics is the study of stable alterations in gene expression that
take place during development by random change or under the
influence of the environment (Jaenisch and Bird, 2003; Tammen
et al., 2013). Epigenetic processes can contribute to the presen-
tation of depressive disorders and the effects of antidepressant
treatments (Bale et al., 2010; Purcell, 2013; Tansey et al., 2013). Lit-
tle is currently known, however, regarding their impact on TRD.
Stewart et al. (2009) examined possible epigenetic interactions
between the genotype of angiotensin converting enzyme (ACE)
and antidepressant effects of ECT in subjects with well-established
TRD and found no evidence for such a relationship. Shifting the
paradigm to include previously untreated, depressed subjects in
the analysis would expand the study of epigenetic mechanisms
and the risks of the development of TRD.
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CENTRAL BIOMARKERS
CEREBROSPINAL FLUID
Monoamine oxidase (MAO) degrades biogenic amines and has
been a central topic of depression research for almost 50 years
(Schildkraut, 1965). In brain, molecules degraded by type A MAO
(MAOA) appear in the cerebrospinal fluid (CSF). Aklillu et al.
(2009) determined whether the concentration of monoamine
metabolites in CSF differs between depressed subjects with or
without well-established TRD. They found elevated concentra-
tions of a dopamine metabolite, homovanillic acid, in the CSF
of TRD subjects, but again, the post hoc design of the study
failed to provide evidence on whether the biomarker can predict
the risk of TRD in untreated, depressed subjects. A large-scale
research project on potential biomarkers of TRD has recently
been announced in which brain imaging of MAOA will take place
(http://clinicaltrials.gov/ct2/show/NCT01031810); however, also
this study follows a post hoc experimental design.
STRUCTURAL MAGNETIC RESONANCE IMAGING
Structural magnetic resonance imaging (sMRI) studies are carried
out to estimate the size of brain regions. Many sMRI studies have
been done in depressed subjects and healthy controls (Chen et al.,
2007; Hoflich et al., 2012), but few have been directed specifically
at TRD. Shah and coworkers used sMRI to see whether the size of
brain regions differs between subjects with well-established TRD,
subjects who had recovered from depression, and healthy sub-
jects (Shah et al., 1998, 2002). Their initial data analysis revealed
a reduction in gray matter in the left temporal cortex, including
the left anterior hippocampus, in subjects with TRD compared
to the other two groups (Shah et al., 1998). Some years later, the
same authors did another data analysis and noted enlarged cere-
broventricles and reduced gray matter in several regions of the
left and right hemisphere in TRD subjects compared to the other
two groups combined (Shah et al., 2002). Zhang et al. (2009) also
examined brain structure in subjects who were already known
to suffer from TRD. Using magnetization transfer imaging, they
noted differences between TRD subjects and healthy individuals in
several regions in the right hemisphere. Recently, Liu et al. (2012)
also used sMRI to see whether the size of brain regions differed
between patients with TRD, remitted patients, and healthy sub-
jects. Their data analyses showed differences between groups for
the size of some regions in gray matter and white matter in cere-
bral cortex and cerebellum. There is, however, no way of knowing
whether any of these findings can provide predictive biomarkers
of TRD risk, due to the post hoc nature of experimental paradigms.
One early study deserves special attention, because it used an
appropriate experimental design for determining whether sMRI
can provide predictive biomarkers of TRD. In that study, Simp-
son et al. (1998) examined depressed, elderly subjects at the time
of their initial contact with psychiatric treatment facilities. sMRI
took place as soon as possible after each subject received a diagno-
sis of major depression. The findings revealed a higher prevalence
of white matter hyperintensities in subcortical regions in those
depressed, elderly subjects that subsequently failed to benefit from
at least two trials of adequate doses of two classes of antidepressant
drugs and/or ECT compared with depressed, elderly subjects who
benefited from the treatments. This study shows that potential
biomarkers can be identified for predicting the risk of TRD by
shifting the experimental paradigm away from post hoc designs and
by moving it toward the use of baseline, pretreatment measure-
ments of biological items, followed by regular clinical assessments
and the use of objective symptom rating scales, throughout a
series of carefully planned antidepressant regimes (Fava et al.,
2003).
VASCULAR BRAIN DISEASE
Naish et al. (2006) used MRI procedures to see whether patholog-
ical conditions in the cerebral microvascular contribute to TRD in
subjects with late-onset disease. They measured cerebral angiopa-
thy and the flow velocity of CSF through the cerebral aqueduct
in elderly healthy subjects and depressed subjects with varying
degrees of TRD. Compared to healthy subjects, patients with TRD
had slower flow velocities of CSF through the cerebral aque-
duct and more pronounced cerebral angiopathies, as evidenced by
Virchow–Robin spaces. Naish and coworkers viewed their findings
as evidence for the contribution of microvascular neuropathies in
TRD, but their post hoc experimental design cannot distinguish
between causes and consequences of prolonged and disabling
depressive disorders.
FUNCTIONAL MAGNETIC RESONANCE IMAGING
Li et al. (2012) used a post hoc design in their study of default mode
functional connectivity in subjects with well-established TRD, in
remitted depressed subjects, and in never-depressed healthy sub-
jects. Under resting state functional magnetic resonance imaging
(fMRI) conditions, they found that functional connectivity of
brain regions was generally lower in remitted subjects and in TRD
patients than in healthy subjects under resting state fMRI con-
ditions. TRD patients had decreased functional connectivity in a
network consisting of the left amygdala, anterior cingulate cortex,
right insula, and precuneus cortex. Li and coworkers speculated
that the particular pattern of abnormal functional connectivity in
depressed subjects may constitute a biomarker of TRD, but their
study design precludes statements regarding the value of resting
state fMRI for identifying subjects at risk.
POSITRON EMISSION TOMOGRAPHY
Brain imaging by positron emission tomography (PET) has often
been used to study potential biomarkers of depressive disorders
as well as to investigate potential beneficial effects of antidepres-
sant drugs (Mayberg et al., 2000; Mayberg, 2007; Hoflich et al.,
2012), but PET has rarely been used specifically for studying TRD.
Thus, Smith et al. (2009) used the traditional post hoc design in
their PET study of mirtazapine binding in brain regions of subjects
with well-established TRD and healthy subjects. They found mod-
erately reduced binding of radiolabeled mirtazapine in regions of
the cerebral cortex and basal ganglia of TRD subjects compared
with healthy subjects. Once again, the experimental design pre-
cludes statements regarding possible causal mechanisms linking
reduced neuroreceptor binding and TRD.
CONCLUDING REMARKS
Depressive disorders are complex, heterogeneous, and disabling
conditions that require prompt treatment and appropriate care.
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Our inability to relieve the disabling symptoms of depressive
disorders in many cases has stimulated research directed toward
the development of more effective antidepressant treatments and
improved clinical care (Rothschild, 2003; Rush et al., 2009; Brady
and Insel, 2012; Schlaepfer et al., 2012). One current approach
toward solving these challenges relates to research on biomarkers
of depressive disorders (Frey et al., 2013).
An ultimate goal of biological psychiatry concerns the use
of biomarkers to improve the initial diagnosis and treatment of
depressive disorders (Cardoso de Almeida and Phillips, 2013).
Unfortunately, most studies carried out in the quest for identify-
ing biomarkers of TRD have used a post hoc experimental design,
thereby precluding statements concerning the initial level of risk
of developing treatment resistance. In the author’s view, our cur-
rent lack of information on the initial risk of TRD stems mainly
from the misguided post hoc experimental design of many studies
that tried to identify biomarkers of TRD. To remedy this situation,
the author proposes that a shift take place in the standard para-
digm in biomarker studies of TRD toward examining depressed
subjects at the time of their initial contact with treatment facili-
ties. Systematic administration of antidepressant treatments with
appropriate monitoring procedures in depressed individuals can
be expected to identify biomarkers for predicting the risk level of
treatment resistance. Such information is likely to disclose biolog-
ical targets that can form the basis for developing more effective
antidepressant treatments.
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